Interphase

Testicular Cancer - Global Pipeline Insights, 2022: Featuring Sanofi, Seagen, BioNTech, Context Therapeutics & Leadartis - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 11, 2023
Consumer, Health, Men, Clinical Trials, Oncology, Physical examination, Testicular cancer, News, Prednisone, Ageing, Tubulin, Survival rate, Prognosis, Route, Prostate cancer, Sanofi, European Medicines Agency, Complex, Microtubule, Cell cycle, II, Administration, BioNTech, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Cryptorchidism, Discovery, Epidemiology, Interphase, FDA, Cancer, SE, Knowledge, Carlos Roa, CLDN6, Route of administration, CAR, Risk, Metaphase, History, Food, Apoptosis, Therapy, Patient, RNA, Cabazitaxel, Clinical trial, EMA, Docetaxel, Dietary supplement, Vaccine, Pharmaceutical industry, Testicle

This "Testicular Cancer - Pipeline Insight, 2022" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Testicular Cancer pipeline landscape.

Key Points: 
  • This "Testicular Cancer - Pipeline Insight, 2022" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Testicular Cancer pipeline landscape.
  • Testicular cancer is one of the most common malignancies in men aged 15 to 45 years.
  • Complex environmental and genetic factors are involved in the development of testicular cancer; common risk factors include cryptorchidism, family history of testicular cancer, personal history of testicular cancer in the contralateral testis, age, and ethnicity.
  • Testicular Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Cell Counting Market Report 2022: Growing Biotechnology and Biopharmaceutical Industries Bolsters Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 30, 2022
Health, Biotechnology, Culture, RBC, Growth, WBC, Revenue, Immune system, Prevalence, Hematocrit, Conditional sentence, Hospital, Patient, Cell counting, USD, Interphase, Blood, AIDS, Virus, Cancer, Research, Cell, Hemocytometer, Cell biology, Application, Plasma, Fine chemical, Vaccine, Microscope

The global cell counting market size is expected to reach USD 15.38 billion by 2030 according to a new study.

Key Points: 
  • The global cell counting market size is expected to reach USD 15.38 billion by 2030 according to a new study.
  • Cell counting is vital in calculating cell concentrations for plating in culture, evaluating the results of cell isolation processes, and detecting cell viability.
  • In life science, cell counting methods such as hemocytometers, automated cell counting, and electrical resistance are the most precise ways to count cells.
  • The publisher has segmented the Cell Counting market report based on product, application, end use and region:
    Cell Counting, Product Outlook (Revenue - USD Billion, 2018 - 2030)

Bravo Casino Celebrates Fifth Anniversary with the launch with Bubble Bobble: Reunion

Retrieved on: 
Wednesday, March 30, 2022
Video, Bubble, Bobble, Multimedia, Reunion, Research, Publication, Interphase, COVID-19, Computer, Facebook, Bubble Bobble, Amusement arcade, Casino

Bravo Casino's Bubble Bobble: Reunion combines storytelling elements from the nostalgic game with features from slot machines, a nod to Las Vegas' casino games.

Key Points: 
  • Bravo Casino's Bubble Bobble: Reunion combines storytelling elements from the nostalgic game with features from slot machines, a nod to Las Vegas' casino games.
  • For its anniversary launch, players in the US will be able to win up to 10,000 diamonds worth USD 350 in game rewards.
  • This Next-Gen reunion of the popular game continues the widely successful initial collaboration between Bravo Casino and Taito.
  • Bravo Casino is a global gaming platform by Megata LTD,Taiwan'sleading social casino gaming provider, hybrid developer and operator.

Global Fluorescent in Situ Hybridization Probe Market (2021 to 2026) - Industry Trends, Share, Size, Growth, Opportunity and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Friday, October 29, 2021
Biotechnology, Genetics, Health, Chromosome, Research, Biotechnology, Diagnosis, Technology, Cancer, Industry, Metaphase, FISH, Interphase, Lists of diseases, Growth, COVID-19, R, In situ hybridization, IVD, Prevalence, Non-functional testing, Medical imaging, Microscope, Potash

Fluorescent in Situ Hybridization (FISH) Probe refers to a sub-atomic cytogenetic technique that uses fluorescent probes to visualize genetic materials.

Key Points: 
  • Fluorescent in Situ Hybridization (FISH) Probe refers to a sub-atomic cytogenetic technique that uses fluorescent probes to visualize genetic materials.
  • How has the global fluorescent in situ hybridization (FISH) probe market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global fluorescent in situ hybridization (FISH) probe market?
  • What is the structure of the global fluorescent in situ hybridization (FISH) probe market and who are the key players?

DGAP-News: BLACKHAWK GROWTH'S MINDBIO THERAPEUTICS OPENS WORLD CLASS FACILITY FOR THE PHARMACEUTICAL INDUSTRY

Retrieved on: 
Monday, September 13, 2021
Pathology, Income, Investment, Therapy, University, Drug development, Technology, EEG, Health, SEDAR, MRI, Company, Black Hawk, Intention, Space food, Cannabis, News, CSE, Interphase, Psychiatry, DGAP, BLR, Acquisition, Research, Security (finance), Pharmaceutical industry

MindBio Therapeutics is excited to announce that it will open a world class facility providing research and drug development as a service to the pharmaceutical industry to potential clients in the United States and Canada.

Key Points: 
  • MindBio Therapeutics is excited to announce that it will open a world class facility providing research and drug development as a service to the pharmaceutical industry to potential clients in the United States and Canada.
  • Companies in the psychedelic and pharmaceutical industry can now contract with MindBio Therapeutics for research and drug development on any psychedelic compound.
  • Large pharmaceutical companies are increasingly looking to create synthetics compounds of psychedelics and MindBio Therapeutics has the ideal platform and access to infrastructure to help accelerate this activity.
  • With its exclusive agreement with the University of Auckland, MindBio has access to expansive infrastructure to bring psychedelic medicines to market.